JP2009510165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510165A5 JP2009510165A5 JP2008534614A JP2008534614A JP2009510165A5 JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5 JP 2008534614 A JP2008534614 A JP 2008534614A JP 2008534614 A JP2008534614 A JP 2008534614A JP 2009510165 A5 JP2009510165 A5 JP 2009510165A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- composition according
- agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 16
- 206010021143 Hypoxia Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000001146 hypoxic effect Effects 0.000 claims 10
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 8
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 claims 2
- 241000219198 Brassica Species 0.000 claims 2
- 235000003351 Brassica cretica Nutrition 0.000 claims 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims 2
- OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 235000010460 mustard Nutrition 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical group C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 claims 2
- 229950002376 tirapazamine Drugs 0.000 claims 2
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 claims 1
- KIMCGLHTSSZPNS-UHFFFAOYSA-N 2,3-dinitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O KIMCGLHTSSZPNS-UHFFFAOYSA-N 0.000 claims 1
- YZBAXVICWUUHGG-UHFFFAOYSA-N 2-[[4-[2-[dimethyl(oxido)azaniumyl]ethylamino]-5,8-dihydroxy-9,10-dioxoanthracen-1-yl]amino]-n,n-dimethylethanamine oxide Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCC[N+](C)(C)[O-])=CC=C2NCC[N+](C)([O-])C YZBAXVICWUUHGG-UHFFFAOYSA-N 0.000 claims 1
- XPBJPGMCFKYBBV-UHFFFAOYSA-N 2-bromoethyl-[2-hydroxy-3-(2-nitroimidazol-1-yl)propyl]azanium;bromide Chemical compound Br.BrCCNCC(O)CN1C=CN=C1[N+]([O-])=O XPBJPGMCFKYBBV-UHFFFAOYSA-N 0.000 claims 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 claims 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- DQMALWRRERBILB-UHFFFAOYSA-N 5-[bis-2(chloro-ethyl)-amino]-2,4-dintro-benzamide Chemical compound NC(=O)C1=CC(N(CCCl)CCCl)=C([N+]([O-])=O)C=C1[N+]([O-])=O DQMALWRRERBILB-UHFFFAOYSA-N 0.000 claims 1
- LWTUZIMLIKOKDI-UHFFFAOYSA-N 7-chloro-n-[3-(2-nitroimidazol-1-yl)propyl]quinolin-4-amine;hydrochloride Chemical compound Cl.[O-][N+](=O)C1=NC=CN1CCCNC1=CC=NC2=CC(Cl)=CC=C12 LWTUZIMLIKOKDI-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- OZNRZINTTRZGCV-UHFFFAOYSA-N [nitro(phenyl)methoxy]phosphonamidic acid Chemical compound NP(O)(=O)OC([N+]([O-])=O)C1=CC=CC=C1 OZNRZINTTRZGCV-UHFFFAOYSA-N 0.000 claims 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims 1
- 150000004056 anthraquinones Chemical class 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical group [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- IGGVVGHJSQSLFO-UHFFFAOYSA-N indole-5,6-quinone Chemical compound O=C1C(=O)C=C2C=CNC2=C1 IGGVVGHJSQSLFO-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 claims 1
- 229950010514 misonidazole Drugs 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72318305P | 2005-10-03 | 2005-10-03 | |
| PCT/US2006/038553 WO2007041546A2 (en) | 2005-10-03 | 2006-09-29 | Method for selectively depleting hypoxic cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510165A JP2009510165A (ja) | 2009-03-12 |
| JP2009510165A5 true JP2009510165A5 (enExample) | 2009-11-05 |
Family
ID=37826084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534614A Pending JP2009510165A (ja) | 2005-10-03 | 2006-09-29 | 低酸素細胞を選択的に枯渇させるための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090136521A1 (enExample) |
| EP (1) | EP1931769A2 (enExample) |
| JP (1) | JP2009510165A (enExample) |
| CA (1) | CA2624707A1 (enExample) |
| WO (1) | WO2007041546A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| NZ549831A (en) * | 2006-09-11 | 2009-03-31 | Auckland Uniservices Ltd | Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer |
| WO2008033039A1 (en) * | 2006-09-11 | 2008-03-20 | Adam Vorn Patterson | Cancer treatment |
| JP5696266B2 (ja) | 2007-11-20 | 2015-04-08 | ランケナー インスティテュート フォー メディカル リサーチ | ジスルフィド化学療法剤およびその使用方法 |
| CN101683319B (zh) * | 2008-09-24 | 2012-09-05 | 杭州民生药业有限公司 | 一种替拉扎明非肠道给药含水制剂及其制备方法 |
| JP5765634B2 (ja) * | 2008-10-21 | 2015-08-19 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | 低酸素活性化型プロドラッグを用いるがんの処置 |
| EP2430178B1 (en) | 2009-05-15 | 2014-07-09 | Lankenau Institute for Medical Research | Methods and kits for measuring toxicity and oxidative stress in live cells |
| US8269197B2 (en) | 2009-07-22 | 2012-09-18 | Intraop Medical Corporation | Method and system for electron beam applications |
| CN102933258A (zh) * | 2010-03-01 | 2013-02-13 | 因特奥普医药公司 | 与含氧量低的细胞敏化剂联用的放疗 |
| RU2597844C2 (ru) | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
| WO2013096687A1 (en) | 2011-12-22 | 2013-06-27 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| WO2015013448A1 (en) | 2013-07-26 | 2015-01-29 | Threshold Pharmaceuticals, Inc. | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
| US9808011B2 (en) | 2014-12-15 | 2017-11-07 | Biovectra Inc. | Pentacyclic triterpene compounds and uses thereof |
| CA2990665A1 (en) | 2015-06-24 | 2016-12-29 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794742A (fr) * | 1972-02-01 | 1973-07-30 | Bayer Ag | Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition |
| US3957779A (en) * | 1972-11-15 | 1976-05-18 | Bayer Aktiengesellschaft | Benzo-1,2,4-triazines |
| US5175287A (en) * | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US5672702A (en) * | 1995-12-04 | 1997-09-30 | Sanofi | Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide |
| AU6178198A (en) * | 1997-03-07 | 1998-09-22 | Sanofi Pharmaceuticals, Inc. | Method of treating a tumor |
| EP1068338A2 (en) * | 1998-03-06 | 2001-01-17 | Oxford Biomedica (UK) Limited | Enhanced prodrug activation |
-
2006
- 2006-09-29 EP EP06816085A patent/EP1931769A2/en not_active Withdrawn
- 2006-09-29 WO PCT/US2006/038553 patent/WO2007041546A2/en not_active Ceased
- 2006-09-29 CA CA002624707A patent/CA2624707A1/en not_active Abandoned
- 2006-09-29 JP JP2008534614A patent/JP2009510165A/ja active Pending
- 2006-09-29 US US11/992,898 patent/US20090136521A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| US12098139B2 (en) | Chemokine receptor modulators and uses thereof | |
| US11433137B2 (en) | Compounds for treating cancer | |
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| JP2009510165A5 (enExample) | ||
| US10166246B2 (en) | TGR5 agonist complexes for treating diabetes and cancer | |
| US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
| Zhang et al. | Targeting role of glioma stem cells for gliobastoma multiforme | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2015534946A5 (enExample) | ||
| Yotnda et al. | Hypoxic tumors and their effect on immune cells and cancer therapy | |
| Shen et al. | HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma | |
| Shi et al. | An overview of heavy chain ferritin in cancer | |
| US12240837B2 (en) | Chemokine receptor modulators and uses thereof | |
| CN111789868A (zh) | 青蒿素类化合物在促进嵌合抗原受体t细胞治疗中的应用及药物组合物 | |
| JP2009538935A5 (enExample) | ||
| US20250042922A1 (en) | Kras modulating compounds | |
| JP2016502527A5 (enExample) | ||
| CN104147036B (zh) | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| US20190060330A1 (en) | Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs | |
| CN118903175B (zh) | 小分子药物联用在增强低氧条件下nk细胞的代谢、杀伤能力中的应用 | |
| Wang et al. | IDDF2022-ABS-0176 Tumor-derived iron loaded-exosomes impair CD8+ T anti-tumor ability via ferroptosis in hepatocellular carcinoma | |
| Alshaker et al. | PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel | |
| WO2021143754A1 (zh) | 用于癌症治疗的组合及其应用 |